文献速递乳房整形与再造美容整形

肿瘤整形保乳缩乳手术降低再手术率且不增加内科风险

Oncoplastic breast reduction surgery decreases rates of reoperation with no increased medical risk.
PubMed 文献 · J Plast Reconstr Aesthet Surg · 2023-11-04

本研究基于全国保险数据库比较肿瘤整形保乳缩乳手术(OBRS)与单纯保乳手术的肿瘤学、内科及外科结局,匹配后每组各15134例。OBRS组重复保乳或后续乳房切除更少(15.2% vs 12.2%,p<0.001),OBRS与重复保乳几率降低相关(OR=0.71,95%CI 0.66-0.77,p<0.001),后续乳房切除几率无显著增加(OR=1.01,95%CI 0.91-1.11,p=0.914)。OBRS组90天外科并发症如裂开、感染、脂肪坏死、乳房脓肿及抗生素处方更高(p<0.001),但任何内科并发症更少(3.7% vs 4.5%,p=0.001)。

要点

  • OBRS组重复保乳或后续乳房切除更常见于保乳组(15.2% vs 12.2%,p<0.001)。
  • OBRS与重复保乳几率降低相关(OR=0.71,95%CI 0.66-0.77,p<0.001)。
  • OBRS组内科并发症更少(3.7% vs 4.5%,p=0.001),但外科并发症更高(p<0.001)。

核心结论

  • OBRS与以保乳形式进行的再手术风险降低相关,且未增加后续乳房切除的可能性。
  • 尽管OBRS与伤口并发症增加相关,但内科并发症发生频率更低。
  • 本研究支持在保乳或OBRS均合适时增加对OBRS的考虑。

研究设计与样本

  • 基于全国保险数据库的查询研究,通过现行 procedural terminology(CPT)代码筛选接受保乳伴或不伴同日乳房缩乳的患者。
  • 按肥胖、体重指数范围、年龄、地区、新辅助化疗进行匹配后比较结局。
  • 保乳组421455例,OBRS组15909例;匹配后每组各15134例。

主要发现

  • 保乳组重复保乳或后续乳房切除更常见(15.2% vs 12.2%,p<0.001)。
  • OBRS组90天外科并发症包括裂开、感染、脂肪坏死、乳房脓肿及抗生素处方更高(p<0.001)。
  • OBRS组任何内科并发症更少(3.7% vs 4.5%,p=0.001)。
  • 逻辑回归显示OBRS与重复保乳几率降低相关(OR=0.71,95%CI 0.66-0.77,p<0.001),后续乳房切除几率无显著增加(OR=1.01,95%CI 0.91-1.11,p=0.914)。

关键数值与推荐

  • 重复保乳或后续乳房切除率:保乳组15.2% vs OBRS组12.2%(p<0.001)。
  • 任何内科并发症率:OBRS组3.7% vs 保乳组4.5%(p=0.001)。
  • 重复保乳的OR=0.71(95%CI 0.66-0.77,p<0.001);后续乳房切除的OR=1.01(95%CI 0.91-1.11,p=0.914)。

临床怎么用

  • 作者认为,当保乳或OBRS均合适时,应增加对OBRS的考虑。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The purpose of this study is to compare the oncologic, medical, and surgical outcomes of lumpectomy versus oncoplastic breast reduction surgery (OBRS) on a national scale. A national insurance-based database was queried for patients who had a lumpectomy with or without a same-day breast reduction by Current Procedural Terminology (CPT) codes. Patients were then matched by obesity, body mass index range, age, region, neoadjuvant chemotherapy, and outcomes were compared. There were 421,455 patients in the lumpectomy group and 15,909 patients in the OBRS group. After matching, 15,134 patients were identified in each group. Repeat lumpectomy or subsequent mastectomy was more common in the lumpectomy group (15.2% vs. 12.2%, p < 0.001). OBRS patients had higher rates of 90-day surgical complications including dehiscence, infection, fat necrosis, breast abscesses, and antibiotic prescription (p < 0.001). Meanwhile, any medical complication was less common in the OBRS group (3.7% vs. 4.5%, p = 0.001). Logistic regression revealed that OBRS was associated with decreased odds of repeat lumpectomy (OR = 0.71, 95% CI 0.66-0.77, p < 0.001) with no significant increased odds of subsequent mastectomy (OR = 1.01, 95% CI 0.91-1.11, p = 0.914). OBRS was found to be associated with decreased risk for reoperation in the form of lumpectomy without increased likelihood of subsequent mastectomy. Although OBRS was associated with increased wound complications, medical complications were found to occur less frequently. This study endorses increased consideration of OBRS when lumpectomy or OBRS is appropriate.

来源:J Plast Reconstr Aesthet Surg,查看原文。版权归原作者所有。

引用

  1. Kilmer LH, Weidman AA, DeGeorge BR, et al. Oncoplastic breast reduction surgery decreases rates of reoperation with no increased medical risk. J Plast Reconstr Aesthet Surg. 2023. PMID: 38016264. doi:10.1016/j.bjps.2023.10.134

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。